Antimicrobial Drug Discovery Through Bacteriophage Genomics

Greg Moeck
Targanta Therapeutics
gmoeck@targanta.com

May 23, 2006

Targanta Therapeutics

Phage-Inspired Drug Discovery Approach



Liu et al., 2004. Nature Biotech. 22:185

Targanta Therapeutics

Update On Recent Data

- Target validation by phage polypeptides
- Identification of small molecule inhibitors
- Optimization of inhibitors via medicinal chemistry
- Two examples:
  - *S. aureus* DNA replication target: DNA polymerase β subunit
  - *S. aureus* transcription target: primary sigma factor RpoD

S. aureus DNA Replication Target: DNA Polymerase β Subunit

Expression of ORF168 in *S. aureus* is Bactericidal

- Dot screening → phage open reading frames that inhibit growth when expressed within *S. aureus*
- Broth assay → rapid killing kinetics of selected phage ORFs:



Targanta Therapeutics

Expression of ORF168 in *S. aureus* Selectively Inhibits DNA Synthesis

• Macromolecular synthesis assay in *S. aureus* → selectivity of inhibition:



Targanta Therapeutics

The Bacterial DNA Replication Machinery Offers Essential, Under-Exploited Targets



Targanta Therapeutics

Affinity Chromatography Identifies Replication Machinery Targets for Phage Polypeptides



***S. aureus* phage polypeptide**
***P. aeruginosa* phage polypeptide**

Targanta Therapeutics

Phage Polypeptide Binding Site on β Appears to be Shared by Replicase Components

- TR-FRET fluorescence assay → study competitors of the interaction:





Targanta Therapeutics

Does Phage Polypeptide Binding to β have a Functional Consequence?



Clamp loader **β** **PolC** **Processive DNA replication**



Clamp loader **β** **PolC** **ORF**

Targanta Therapeutics

β-binding Phage Polypeptides Inhibit the *S. aureus* DNA Replicase *in vitro*

• Plate-based assay with reconstituted replicase → study effect of phage polypeptides on processive DNA synthesis *in vitro*:



Targanta Therapeutics

Enzyme-Based Screens for Small Molecule Inhibitors Exploit Essential Activities of the Replicase



Targanta Therapeutics

In vitro Activities of Two *S. aureus* Replicase Inhibitors

	Compound 1	Compound 2
IC_{50} (µM), *S. aureus* replicase	18 ± 7.1	7.9 ± 0.2
IC_{50} (µM), mammalian DNA replicase	>50	>50
IC_{50} (µM), DNA binding assay	>50	>50
IC_{50} (µM), HeLa cytotoxicity assay	>100	14
MIC (µg/mL)		
• *S. aureus* ATCC 13709 (MSSA)	4	8
• *S. aureus* ATCC 13709 + 4% HSA	64	64
• *M. bovis* BCG (Denmark, Phipps)	4	n.d.
• *H. influenzae* ATCC 49766	>32	>128
Structure		

Targanta Therapeutics

Summary

- **ORF168 and ORF240 polypeptides:**
  - inhibit DNA synthesis selectively in *S. aureus*
  - bind selectively to the *S. aureus* DNA sliding clamp *in vitro*
  - inhibit processive DNA replication *in vitro*

- **Small-molecule inhibitors from replicase screen**:
  - active *in vitro* against G+ including MRSA, and efflux-deficient G-
  - validate the replicase for further inhibitor screening
  - suffer from serum shift
  - lack efficacy in rigorous models of *S. aureus* infection

- **Additional series are under study**

S. aureus Transcription Target: Primary Sigma Factor RpoD

S. aureus RpoD is the target of phage polypeptide ORF67

- ***S. aureus* RpoD:**
  - primary sigma factor in transcription machinery
  - ortholog of *E. coli* σ^{70}
  - essential for *S. aureus* viability
  - is targeted by phage polypeptide ORF67



Targanta Therapeutics

RpoD-Specific Phage Polypeptide (ORF67) Inhibits *S. aureus in vitro* Transcription

• Plate-based assay with purified *S. aureus* RNAP → study effect of phage polypeptides on RNA synthesis *in vitro* and conduct HTS:





Targanta Therapeutics

Transcription Screen Identifies a Novel Ureidothiophene Carboxylate Inhibitor



⇒ IC50 (*in vitro S. aureus* transcription):	0.73 µM
⇒ MIC (*S. aureus* Smith ATCC 13709):	1 µg/mL
⇒ MIC (50% serum):	>128 µg/mL
⇒ Spectrum:	limited to Staphylococci
⇒ IC50 (*in vitro* HeLa cytotoxicity):	>100 µM
⇒ IC50 (*E. coli in vitro* transcription):	>100 µM
⇒ IC50 (mammalian *in vitro* transcription):	>100 µM

Ester Variations and Activity



IC50 0.73 µM
MIC 1 µg/mL (Smith)

- Ester functionality is necessary
  - amides, ketones, alcohols, acid tested
- Polar groups are undesirable
  - small heterocycles +/- charge tested
- **Isopropyl ester is optimum:**



IC50 1.0 µM
MIC >128 µg/mL



IC50 0.06 µM
MIC 1 µg/mL



IC50 0.22 µM
MIC 1 µg/mL



IC50 0.14 µM
MIC >128 µg/mL

Targanta Therapeutics

Ureidothiophene Carboxylate Inhibits Transcription in Growing *S. aureus* Cells

• Macromolecular synthesis assay in *S. aureus* → Ureidothiophene carboxylate inhibits RNA and protein synthesis similarly to Rifampicin:

Ureidothiophene carboxylate



Rifampicin



Targanta Therapeutics

Ureidothiophene Carboxylate is Active Against Antibiotic Resistant Strains of *S. aureus*

Resistant Category	***n***	**MIC or MIC range (μg/mL)**
Mupirocin-resistant	12	0.5 (11 strains) >128 (1 strain)
Rifampicin-resistant	9	< 0.125 - 1
MRSA	14	0.25 - 2
VISA ATCC 700699	1	0.25

- *Activity against Rif^{R} strains suggests distinct binding site or mechanism*

Urea Variations and Activity



IC50 0.06 µM
MIC 0.5 µg/mL (Smith)

- Urea functionality is necessary; amides, carbamates, thioureas, sulfuric diamides lose inhibitory activity
- Replacement of phenyl ring with alicyclics or heterocyclics abolishes antibacterial activity
- Substituents on phenyl group abolish antibacterial activity
  - meta, para substituents retain inhibitory activity
  - ortho substituents destroy inhibitory activity

➢ Only thiophenes are tolerated as phenyl replacements:



IC50 0.06 µM
MIC 0.5 µg/mL



IC50 0.20 µM
MIC 0.5 µg/mL



IC50 0.49 µM
MIC 1 µg/mL

Ring Variations and Activity



IC50 0.06 µM
MIC 0.5 µg/mL
(Staphylococci)

- Heteroatoms in ring abolish antibacterial activity
- Acyclic replacements are detrimental (IC50 5-10 µM)
- **Eight and nine membered rings optimum:**



IC50: 2.4 µM
MIC >128 µg/mL



IC50: 0.1 µM
MIC 1 µg/ml
(*S. aureus* Smith only)



IC50: 0.06 µM
MIC 0.5 µg/mL
(Staphylococci)



IC50: 0.05 µM
MIC 0.5 µg/mL
(Staphylococci)



IC50: 0.14 µM
MIC >128 µg/mL

Targanta Therapeutics

Ureidothiophene Carboxylate - Summary



IC50 0.06 µM
MIC 0.5 µg/mL

- >120 compounds made in 6 month campaign
- Compound is likely only active against staphylococci and is subject to high frequencies of resistance
- Well-tolerated in mice at 2x25 mg/kg i.v. bolus
- Active in a low-stringency mouse model of systemic *S. aureus* infection (i.p. infection / i.p. injection)
- Additional SAR of hydrophobic ring required to address serum binding issue

Acknowledgements

Targanta's CSO

Thomas Parr

Targanta Biology

Adam Belley
Francis Arhin
Ingrid Sarmiento
Ibtihal Fadhil
Jothi Krishnamoorthy
Daniel Williams
Sylvain Beaulieu
Mohammed Dehbi
Ramakrishnan Srikumar
Pascale Bauda
Nhuan Ha
Elena Vaisburg
Karine Laquerre
Dominique Mayaki
Mario Callejo
Dario Lehoux
Jing Liu
Geoff McKay
Dimitri Vzdornov
Valérie Ostiguy
Hugo Poirier

Targanta Chemistry

Adel Rafai Far
Ranga Reddy
Dilip Dixit
Yanick Lafontaine
Anik Dubois
Stéphane Ciblat
Odette Bélanger
Daniel Delorme
Tom Houghton
Claude Metayer
Yannick Rose
Evelyne Dietrich
Kelly Tanaka
Ting Kang

Targanta's Founders

Jerry Pelletier
Philippe Gros
Michael Dubow

Natural Sciences and Engineering Research Council of Canada (NSERC)